SCHEMBL30608064

SCHEMBL30608064

N#Cc1c(N)c2ccc(I)cc2n(-c2ccccc2)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.45
▸ POLB P06746 2/20 0.45
▸ HPGD P15428 3/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ KDM4E B2RXH2 7/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.37
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ USP2 O75604 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ CASP1 P29466 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ CASP7 P55210 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ G6PD P11413 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26127178 1.00 ALDH1A1 (0.45) ALDH1A1POLBHPGDCYP1A2CYP2C9
SCHEMBL30608069 0.85 MAPK8 (0.49) ALDH1A1POLBHPGDCYP1A2CYP2C9
SCHEMBL26125920 0.85 MAPK8 (0.49) ALDH1A1POLBHPGDCYP1A2CYP2C9
SCHEMBL26125404 0.85 HPGD (0.54) ALDH1A1POLBHPGDCYP1A2CYP2C9
SCHEMBL30608067 0.85 HPGD (0.54) ALDH1A1POLBHPGDCYP1A2CYP2C9
SCHEMBL26127364 0.84 HPGD (0.48) ALDH1A1POLBHPGDCYP1A2CYP2C9
SCHEMBL30608109 0.84 HPGD (0.48) ALDH1A1POLBHPGDCYP1A2CYP2C9
SCHEMBL30608124 0.81 MAT2A (0.48) ALDH1A1POLBHPGDCYP1A2CYP2C9
SCHEMBL26125895 0.81 MAT2A (0.48) ALDH1A1POLBHPGDCYP1A2CYP2C9
SCHEMBL30608128 0.81 MAT2A (0.44) ALDH1A1POLBHPGDCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND SHOUYAO HOLDINGS BEIJING CO LTD (CN) 2025-07-10 — — US disclosed
EP-4501912-A1 NOVEL HETEROCYCLIC COMPOUND Shouyao Holdings (Beijing) Co., Ltd. (CN) 2025-02-05 — — EP disclosed
CN-118475560-A Novel heterocyclic compound 首药控股(北京)股份有限公司 2024-08-09 — — CN disclosed
CN-116924983-A Novel heterocyclic compound 首药控股(北京)股份有限公司 2023-10-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND MAPT, MNAT1, MAT2A ALDH1A1 996/4885POLB 2863/4885HPGD 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback